HDAC9 and neoplasm: Together, these results indicate that low-dose TSA may facilitate tumor regression by abrogating pro-tumoral TAM functions in mice, supporting the role of HDAC inhibition in enhancing a T cell-supportive TAM phenotype in vivo.